证券代码：688151 证券简称：华强科技 公告编号：2024-021 湖北华强科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 召开日期时间：2024 年 5 月 17 日 14 点 00 分 召开地点：中国（湖北）自贸区宜昌片区生物产业园东临路 499 号会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 17 日 至 2024 年 5 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 1 股东大会召开日期：2024年5月17日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） ...

Financial Performance - Total operating revenue for 2023 was corrected to ¥57,275.31 million, a decrease of 2.21% from the previous year's ¥58,567.94 million[1]. - Operating profit was revised to ¥477.45 million, reflecting a significant decline of 92.52% compared to ¥6,387.20 million in the prior year[1]. - Total profit was adjusted to ¥414.26 million, down 93.41% from ¥6,287.89 million year-over-year[1]. - Net profit attributable to shareholders was corrected to ¥792.51 million, an 88.36% decrease from ¥6,807.26 million in the previous year[1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was revised to -¥7,602.74 million, a drastic change from -¥1,292.02 million in the prior year, indicating a decline of 488.44%[1]. - Basic earnings per share remained at ¥0.02, down 90% from ¥0.20 in the previous year[1]. - Total assets at the end of the reporting period were corrected to ¥505,164.53 million, a decrease of 2.13% from ¥516,166.15 million at the beginning of the period[1]. Regulatory and Compliance Issues - The company received regulatory warnings from the Hubei Securities Regulatory Bureau and the Shanghai Stock Exchange regarding the need for corrections in previous financial reports[4]. - The company expressed sincere apologies to investors for the impact of the earnings report correction[7]. - The board will enhance supervision and training on financial accounting standards to improve the quality of financial information[8].

Financial Performance - The company reported a net profit attributable to shareholders of RMB 68,072,565.20 for the year 2022, with a cash dividend payout ratio of 38.31%[5]. - The company's operating revenue for 2022 was ¥585,679,394.08, a decrease of 54.05% compared to ¥1,274,716,156.37 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥68,072,565.20, down 78.67% from ¥319,190,437.72 in 2021[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,920,211.20, a decline of 104.76% compared to ¥271,684,550.93 in 2021[21]. - The net cash flow from operating activities decreased by 138.38%, resulting in -¥181,302,862.18 for 2022[24]. - The gross profit margin for the main business was 19.84%, a decrease of 22.86 percentage points year-on-year[78]. - The revenue from military products decreased by 49.97% year-on-year due to delays in military procurement plans[80]. - The company reported a large accounts receivable balance of CNY 638.89 million, accounting for 14.71% of current assets[78]. - The company’s main business revenue for the reporting period was 534.28 million RMB, a decrease of 57.60% year-on-year[89]. - The net cash flow from investment activities decreased by 2,018.34% year-on-year, primarily due to investments in structured deposits[87]. Dividend Policy - As of December 31, 2022, the total distributable profit was RMB 254,046,178.44, with a proposed cash dividend of RMB 0.757 per share (before tax) based on a total share capital of 344,500,000 shares[5]. - The company plans to maintain the total dividend amount even if there are changes in total share capital before the dividend distribution date, adjusting the per-share distribution accordingly[5]. - The company maintains a cash dividend policy that requires at least 20% of the distributable profit to be allocated as cash dividends, barring special circumstances[180]. - The company emphasizes a stable and continuous profit distribution policy, balancing investor returns with sustainable development[179]. - The board of directors is responsible for discussing and proposing the profit distribution plan, which must be approved by the shareholders' meeting[180]. Risk Management - The company has outlined various operational risks and corresponding mitigation strategies in the report, emphasizing the importance of risk management[4]. - The company has confirmed that there are no violations of decision-making procedures regarding external guarantees, ensuring compliance with regulations[8]. - The company faced significant revenue declines due to delays in military equipment orders and a drop in demand for vaccine-related products[24]. - The company is at risk of losing its competitive edge if it fails to invest adequately in R&D or if new product development cycles are too long[75]. - The company faces risks of order delays in special protective equipment due to the postponement of the "14th Five-Year" procurement plan[72]. Research and Development - The company's R&D investment as a percentage of operating revenue increased by 6.72 percentage points to 11.34% in 2022[23]. - The total R&D investment for the year was approximately ¥66.39 million, representing a 12.68% increase from the previous year, and accounting for 11.34% of total revenue[59]. - The number of R&D personnel increased to 139, making up 19.58% of the total workforce, compared to 17.96% in the previous year[65]. - The company has developed 15 core technologies, including integrated design technology for respiratory devices and early warning models for filter canister failure[55]. - The company is actively involved in research and development for next-generation military equipment, contributing to the modernization of national defense capabilities[47]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance, indicating a standard governance structure[6]. - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal requirements and maintaining effective governance[137]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards and effective decision-making[137]. - The supervisory board has held five meetings, ensuring compliance and protecting the rights of the company and its shareholders[138]. - The company established an internal control system to enhance risk prevention and operational standards[139]. Market and Industry Trends - The special protection industry is experiencing rapid growth due to increasing defense budgets and the rising demand for advanced equipment in response to nuclear and biochemical threats[45]. - The global pharmaceutical market is expected to exceed $150 billion by 2025, driven by population growth and aging demographics[48]. - The pharmaceutical packaging industry is expected to grow due to the increasing health awareness and aging population in China, providing significant opportunities for the upstream packaging materials sector[126]. - The market for nuclear and biochemical safety equipment is projected to grow due to increased demand from emergency response organizations and policy support[123]. - The competitive landscape in the military supplies industry is intensifying as more companies enter the market following the reduction of entry barriers[124]. Strategic Initiatives - The company is focusing on digital transformation with a "1331" action plan, aiming for a systematic approach to enhance digital capabilities and support the transition to smart factories[37]. - The company is committed to building an independent innovation system and increasing R&D investment to enhance its technological capabilities[129]. - The company is actively expanding into civilian markets, including medical packaging and medical devices, leveraging its technological advantages[68]. - The company plans to enhance its supply chain efficiency, aiming for a 15% reduction in operational costs by the next fiscal year[152]. - The company is committed to enhancing investor communication through various channels, including performance briefings and interactive platforms[139].

华泰联合证券有限责任公司 关于湖北华强科技股份有限公司 2023 年度现场检查报告 根据中国证监会《证券发行上市保荐业务管理办法》和《上海证券交易所上 市公司自律监管指引第 11 号——持续督导》等有关法律法规的要求，华泰联合 证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为湖北华强 科技股份有限公司（以下简称"华强科技"或"公司"）首次公开发行股票并在 科创板上市的保荐机构，于 2024 年 4 月 8 日至 2024 年 4 月 18 日对公司 2023 年度有关情况进行了现场检查。现将本次现场检查情况报告如下： 一、本次现场检查的基本情况 华泰联合证券针对华强科技实际情况制订了 2023 年度现场检查工作计划。 为顺利实施本次现场工作，提高现场工作效率，切实履行持续督导工作，华泰联 合证券于 2024 年 4 月 8 日以书面形式将现场检查事宜通知湖北华强科技股份有 限公司，并要求公司提前准备现场检查工作所需的相关文件和资料。 2024 年 4 月 8 日至 18 日，华泰联合证券现场检查人员根据事先制订的现场 检查工作计划，采取与公司高级管理人员进行沟通和询问、查看公司生产经营场 所和募 ...

湖北华强科技股份有限公司 2023 年 度 涉 及 财 务 公 司 关 联 交 易 的 存 款 、 贷款等金融业务的专项说明 天职业字[2024]30594 号 ll 录 涉 及 财 务 公 司 关 联 交 易 的 存 款 、 贷 款 等 金 融 业 务 的 专 项 说 明 --- 1 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://zq.cnof.cov.cn）"进行主 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://zq.nof.gov.cn）"进行进行 关于湖北华强科技股份有限公司 2023 年度涉及财务公司关联交易的存款、贷款等金融业务的专项说明 天职业字[2024]30594 号 湖北华强科技股份有限公司全体股东: 我们接受委托,审计了湖北华强科技股份有限公司及其子公司(以下简称"华强科技"或 "公司")2023年12月31日的合并及母公司资产负债表、2023年度的合并及母公司利润表、 合并及母公司股东权益变动表、合并及母公司现金流量表和财务报表附注(以下简称"财务报 表"),并于 2024年4月25 日出具了"天职业字[2024]17881 号"的标 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥121,337,392.45, a decrease of 36.75% compared to the same period last year[3] - The net profit attributable to shareholders was ¥14,146,460.31, down 17.38% year-on-year[3] - The net profit after deducting non-recurring gains and losses was -¥7,531,027.53, reflecting a significant decline of 198.33%[3] - The net cash flow from operating activities was -¥85,487,838.04, a decrease of 4.32% compared to the previous year[3] - Total operating revenue for Q1 2024 was CNY 121,337,392.45, a decrease of 36.7% compared to CNY 191,850,331.44 in Q1 2023[17] - Net profit for Q1 2024 was CNY 14,146,460.31, a decline of 17.3% from CNY 17,123,244.96 in Q1 2023[18] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.04, down from CNY 0.05 in Q1 2023[19] Cash Flow and Liquidity - The net cash flow from operating activities was -$85,487,838.04, compared to -$81,949,557.53 in the previous year, indicating a decline in operational cash flow[22] - The net increase in cash and cash equivalents was -$1,466,870,500.46, compared to -$1,155,142,168.75 in the previous year, reflecting a significant decrease in liquidity[23] - The ending balance of cash and cash equivalents was $258,634,672.00, down from $1,390,354,676.23 in the previous year[23] - Cash received from operating activities totaled $138,056,599.35, while cash paid for operating activities was $223,544,437.39, leading to a negative cash flow from operations[22] - The company reported cash received from tax refunds amounting to $4,877,257.86, which is a key component of operational cash inflow[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,990,670,797.13, a decrease of 1.21% from the previous year-end[4] - The total current assets as of March 31, 2024, amount to ¥3,631,738,369.33, a decrease from ¥3,807,389,370.64 as of December 31, 2023, representing a decline of approximately 4.6%[12] - The cash and cash equivalents decreased to ¥953,118,858.26 from ¥2,408,551,560.14, indicating a significant reduction of about 60.4%[12] - Total liabilities as of Q1 2024 amounted to CNY 806,540,149.95, down from CNY 881,385,462.89 in the previous period[15] - The total assets as of March 31, 2024, are ¥4,990,670,797.13, down from ¥5,051,645,259.93, reflecting a decrease of approximately 1.2%[13] Research and Development - R&D investment totaled ¥14,368,760.86, representing 11.84% of operating revenue, an increase of 4.95 percentage points[4] - Research and development expenses for Q1 2024 were CNY 14,368,760.86, slightly up from CNY 13,226,047.55 in Q1 2023[17] Market and Strategic Developments - The company experienced a significant decline in medical device sales due to the recovery from public health events, impacting revenue recognition[6] - The company has not reported any new product developments or technological advancements in the current quarter[11] - There are no significant market expansion or acquisition strategies mentioned in the current report[11] - The company has not provided any forward-looking guidance or performance outlook for the upcoming quarters[11] Shareholder Information - The top two shareholders are China Ordnance Equipment Group with 45.52% and Southern Industrial Asset Management with 24.83% of shares[8] Non-Recurring Gains - Non-recurring gains totaled ¥21,677,487.84, influenced by a 129.04% increase in fair value changes of structured deposits[6]

湖北华强科技股份有限公司 关于营业收入扣除情况的专项核查意见 天职业字[2024]30597 号 目 录 2023 年度营业收入扣除情况的专项核查意见 --- -1 2023 年度营业收入扣除情况表— -3 _ 您可使用手机 " --- 关于对湖北华强科技股份有限公司 2023 年度营业收入扣除情况的专项核查意见 天职业字[2024]30597 号 湖北华强科技股份有限公司全体股东: 我们接受湖北华强科技股份有限公司(以下简称"华强科技"或"公司")委托,在审 计了华强科技 2023年12月 31日的合并及公司资产负债表,2023年度的合并及公司利润表、 合并及公司现金流量表、合并及公司股东权益变动表以及财务报表附注的基础上,对后附的 由华强科技管理层编制的《2023 年度营业收入扣除情况表》（以下简称"扣除情况表"） 进行了专项核查。 三、专项核查意见 根据我们的工作程序,我们认为,华强科技管理层编制的扣除情况表已按照上市规则的 要求编制,在所有重大方面公允反映了华强科技 2023年营业收入扣除情况及扣除后的营业 收入金额。 关于对湖北华强科技股份有限公司 2023 年度营业收入扣除情况的专项核查意见 天职 ...

湖北华强科技股份有限公司 关于预计2024年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次日常关联交易事项均为公司正常经营业务需要，遵循了公平、公正、 公开的市场原则，交易价格公允合理，不存在损害公司、无关联关系股东及广大 中小股东的合法权益，不会对公司经营及独立性产生影响，公司亦不会因此而对 关联方产生依赖。 重要内容提示： 本次预计2024年度日常关联交易事项需提交股东大会审议。 证券代码：688151 证券简称：华强科技 公告编号：2024-016 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 湖北华强科技股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开 第二届董事会第六次会议，审议通过了《预计 2024 年度日常关联交易的议案》， 董事会会议上，关联董事唐伦科先生、张亚昌先生、邹晓丽女士、徐斌先生回避 表决，其余非关联董事对该议案一致同意。表决程序符合《公司法》、《证券法》 等法律法规以及《公司章程》的有关规定。表决结果：5 票同意，0 票反对，4 票 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[13]. - The company has set a revenue guidance of RMB 1.2 billion for the full year 2022, reflecting an expected growth of 10%[13]. - The company reported a total operating revenue of CNY 343.65 million for the first half of 2022, a decrease of 44.23% compared to the same period last year[19]. - Net profit attributable to shareholders was CNY 96.73 million, down 49.35% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 44.11 million, a decline of 74.13%[22]. - The company's gross profit margin was 28.69%, a decrease of 15.43 percentage points year-on-year, with the main business gross margin at 29.23%, down 15.47 percentage points[22]. - The net cash flow from operating activities was -CNY 130.30 million, a decrease of 313.38% compared to the previous year, primarily due to reduced cash receipts from sales and increased cash payments for raw materials[22]. - The company achieved a 38.37% increase in revenue and an 88.18% increase in sales for medical masks and protective clothing during the reporting period[33]. - The company reported a total operating revenue for the first half of 2022 of CNY 343,645,910.88, a decrease of 44.2% compared to CNY 616,130,514.48 in the same period of 2021[181]. - Net profit for the first half of 2022 was CNY 96,731,172.12, a decline of 49.3% from CNY 190,977,291.94 in the same period of 2021[182]. Research and Development - The company is investing RMB 50 million in R&D for new technologies aimed at enhancing product safety and effectiveness[13]. - The company's R&D expenditure accounted for 10.10% of operating revenue, an increase of 6.68 percentage points compared to the same period last year[21]. - R&D investment totaled approximately ¥34.7 million, a 64.80% increase compared to the previous year, with R&D expenses accounting for 10.10% of total revenue[39]. - The company filed 23 new patent applications during the reporting period, bringing the total authorized patents to 153[35]. - Key projects in core technology research, such as spherical activated carbon and failure warning technology, made effective progress, laying a solid foundation for new product development[29]. - The company has established long-term collaborations with various research institutions and universities to enhance its R&D capabilities[49]. Market Expansion and Product Development - User data indicates a growth in active users by 20% compared to the same period last year, reaching 1.2 million active users[13]. - New product launches include three innovative personal protective equipment (PPE) lines, which are expected to contribute an additional RMB 100 million in revenue by year-end[13]. - The company is actively expanding into the pharmaceutical packaging and medical device markets, leveraging its technological advantages[26]. - The company is focusing on expanding the market for non-COVID vaccine stoppers and promoting new products like rubber components for pre-filled syringes[33]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a budget of RMB 200 million allocated for this purpose[13]. Financial Management and Investments - The company raised a total of ¥3.025 billion in funds, with a net amount of ¥2.812 billion after deducting issuance costs[147]. - The company committed to invest ¥772 million in the new emergency rescue equipment production base project, with a cumulative investment of ¥9.08 million, representing 1.18% of the total commitment[147]. - The company allocated ¥353 million for the construction of a new protective material research platform, with a cumulative investment of ¥868,030, accounting for 0.25% of the total commitment[148]. - The company has not yet defined the investment direction for the remaining raised funds of ¥761.951 million[148]. - The company approved the use of raised funds to replace pre-invested project funds and issuance expenses totaling RMB 29,912,991.66[150]. Shareholder and Corporate Governance - The board has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[7]. - The company has established employee stock ownership platforms to enhance employee engagement and retention[163]. - The company has committed to various share restrictions for its major shareholders and key personnel, with terms ranging from 12 to 42 months[82]. - The company will prioritize cash dividends over stock dividends, ensuring a stable and continuous profit distribution policy[118]. - The controlling shareholder commits to avoiding any substantial competition with the company and will not provide confidential business information to competitors[121]. Risks and Challenges - The company has identified several key risks, including supply chain disruptions and regulatory changes, which may impact future performance[4]. - The company is facing risks related to core competitiveness, including potential delays in product orders and competition from foreign brands in the pharmaceutical packaging sector[57]. - The company’s performance is influenced by macroeconomic factors, market conditions, and changes in military procurement needs, which could affect future revenue[58]. Environmental and Social Responsibility - The management highlighted a focus on sustainability initiatives, aiming to reduce production waste by 25% by the end of 2022[13]. - The company has implemented real-time monitoring of wastewater discharge as part of its environmental responsibility efforts[79]. - The company provided assistance of 185,400 yuan for consumption support and 600,000 yuan in aid to Yanshan County during the reporting period[80].

经核查,独立董事王广昌、刘洪川、刘景伟任职经历以及签署的自查文件,董事 会认为公司独立董事均能够胜任独立董事的职责要求,在担任公司独立董事期间,严 格遵守中国证监会和上海证券交易所的相关规定。上述人员未在公司担任除独立董事 以外的任何职务,也未在公司主要股东公司担任任何职务,与公司以及主要股东之间 不存在利害关系或其他可能妨碍其进行独立客观判断的关系。因此,公司独立董事符 合《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》《上海证 券交易所科创板上市公司自律监管指引第1号 -- 规范运作》中对独立董事独立性的 相关规定。 湖北华强科技股 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律监管 指引第1号 -- 规范运作》等要求,并结合独立董事出具的《独立董事独立性自查情 况表》,湖北华强科技股份有限公司(以下简称"公司")董事会,就公司在任独立 董事王广昌、刘洪川、刘景伟的独立性情况进行评估并出具如下专项意见: 湖北华强科技股份有限公司董事会 关于独立董事独立性情况的专项意见 ...